|
03 Apr 2020 |
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
|
|
03 Apr 2020 |
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
|
|
03 Apr 2020 |
Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development
|
|
02 Apr 2020 |
University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma
|
|
02 Apr 2020 |
Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
|
|
02 Apr 2020 |
Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA
|
|
02 Apr 2020 |
Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
|
|
01 Apr 2020 |
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
|
|
01 Apr 2020 |
InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology
|
|
01 Apr 2020 |
Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
|
|
01 Apr 2020 |
Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19
|
|
01 Apr 2020 |
EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients from the SISCO Study
|
|
01 Apr 2020 |
Takeda Receives Positive CHMP Opinion for ADCETRIS in Combination w/ CHP for Adult Patients with Previously Untreated sALCL
|
|
31 Mar 2020 |
I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea
|
|
31 Mar 2020 |
GigaGen Initiates Development of Recombinant Polyclonal Antibody Therapy for COVID-19
|
|
31 Mar 2020 |
Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study
|
|
30 Mar 2020 |
Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
|
|
30 Mar 2020 |
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
|
|
30 Mar 2020 |
Imfinzi approved in the US for extensive-stage small cell lung cancer
|
|
30 Mar 2020 |
Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept
|
|
29 Mar 2020 |
Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
|
|
27 Mar 2020 |
Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
|
|
27 Mar 2020 |
Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors
|
|
26 Mar 2020 |
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
|
|
26 Mar 2020 |
Eisai submits marketing authorization application in Japan for anticancer agent denileukin diftitox (genetic recombinant) for cutaneous T-cell lymphoma and peripheral T-cell lymphoma
|
